StockData
Phibro Animal Health Corp logo

Phibro Animal Health Corp (PAHC) stock

PAHCNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 22/3046% below fair value
$34.92−0.10 (-0.29%)

Close on Nov 17, 2026Market cap $1.42BP/E 14.4Yield 1.37%

Earnings

Phibro Animal Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 3, 2027
Q2 FY2027 · estimated, during market hours
Revenue, Q1 FY2027
$386.80M
+6.3% on a year earlier
Adjusted diluted EPS, Q1 FY2027
$0.79
$0.73 a year earlier
Latest guidance
Issued
Nov 4, 2026 · 7 items

Quarterly results

Revenue and earnings per share from each of Phibro Animal Health's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q2 FY2027ended Dec 31, 2026Feb 3, 2027Expected–––––
Q1 FY2027ended Sep 30, 2026Nov 4, 2026after the close$386.80M+6.3%$0.72$0.79Release
Q4 FY2026ended Jun 30, 2026Aug 26, 2026during market hours$396.70M+4.8%$0.53$0.85Release
Q3 FY2026ended Mar 31, 2026May 6, 2026during market hours$383.50M+10.3%$0.59$0.76Release
Q2 FY2026ended Dec 31, 2025Feb 4, 2026during market hours$373.90M+20.9%$0.67$0.87Release
Q1 FY2026ended Sep 30, 2025Nov 5, 2025during market hours$363.90M+39.7%$0.65$0.73Release
Q4 FY2025ended Jun 30, 2025Aug 27, 2025during market hours$378.70M+38.6%$0.42$0.57Release
Q3 FY2025ended Mar 31, 2025May 7, 2025during market hours$347.80M+32.1%$0.51$0.63Release
Q2 FY2025ended Dec 31, 2024Feb 5, 2025during market hours$309.30M+23.8%$0.08$0.54Release
Q1 FY2025ended Sep 30, 2024Nov 6, 2024during market hours$260.40M+12.6%$0.17$0.35Release
Q4 FY2024ended Jun 30, 2024Aug 28, 2024during market hours$273.20M+7.1%$0.02$0.41Release
Q3 FY2024ended Mar 31, 2024May 8, 2024during market hours$263.20M+7.1%$0.21$0.31Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Phibro Animal Health's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Net salesGAAPFY2027$1.55B – $1.60B–NewNov 4, 2026
Net salesFY2027$1.55B – $1.60B–NewAug 26, 2026
Net sales growthFY2027+4%–NewAug 26, 2026
Adjusted EBITDAnon-GAAPFY2027$258.00M – $268.00M–NewNov 4, 2026
Adjusted EBITDAnon-GAAPFY2027$258.00M – $268.00M–NewAug 26, 2026
Diluted EPSGAAPFY2027$2.98 – $3.22–NewNov 4, 2026
Diluted EPSGAAPFY2027$2.98 – $3.22–NewAug 26, 2026
Adjusted diluted EPSnon-GAAPFY2027$3.41 – $3.59–NewNov 4, 2026
Adjusted diluted EPSnon-GAAPFY2027$3.41 – $3.59–NewAug 26, 2026
Adjusted diluted EPS growthnon-GAAPFY2027+9%–ReaffirmedAug 26, 2026
Adjusted EBITDA growthnon-GAAPFY2027+3%–NewAug 26, 2026
Adjusted effective income tax ratenon-GAAPFY202720%–NewNov 4, 2026
Adjusted effective income tax ratenon-GAAPFY202720%–NewAug 26, 2026
Adjusted net incomenon-GAAPFY2027$140.00M – $147.00M–NewNov 4, 2026
Adjusted net incomenon-GAAPFY2027$140.00M – $147.00M–NewAug 26, 2026
Adjusted net income growthnon-GAAPFY2027+9%–RaisedAug 26, 2026
Diluted EPS growthGAAPFY2027+27%–ReaffirmedAug 26, 2026
Net incomeGAAPFY2027$122.00M – $132.00M–NewNov 4, 2026
Net incomeGAAPFY2027$122.00M – $132.00M–NewAug 26, 2026
Net income growthGAAPFY2027+27%–NewAug 26, 2026

Guidance vs results

The last range Phibro Animal Health gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2026Adjusted diluted EPS$2.98 – $3.10$3.21Σ4QAbove range
FY2026EPS (GAAP)$2.25 – $2.44$2.44Σ4QWithin range
FY2026Revenue$1.46B – $1.50B$1.52BΣ4QAbove range
FY2025Adjusted diluted EPS$1.96 – $2.09$2.09Σ4QWithin range
FY2025EPS (GAAP)$0.98 – $1.11$1.18Σ4QAbove range
FY2025Revenue$1.26B – $1.29B$1.30BΣ4QAbove range

Guidance history

Every forecast Phibro Animal Health put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026Adjusted EBITDAFY2027$258.00M – $268.00MNew
Nov 4, 2026Adjusted diluted EPSFY2027$3.41 – $3.59New
Nov 4, 2026Diluted EPSFY2027$2.98 – $3.22New
Nov 4, 2026Adjusted effective income tax rateFY202720%New
Nov 4, 2026Net incomeFY2027$122.00M – $132.00MNew
Nov 4, 2026Adjusted net incomeFY2027$140.00M – $147.00MNew
Nov 4, 2026Net salesFY2027$1.55B – $1.60BNew
Aug 26, 2026Adjusted EBITDAFY2027$258.00M – $268.00MNew
Aug 26, 2026Adjusted diluted EPSFY2027$3.41 – $3.59New
Aug 26, 2026Diluted EPSFY2027$2.98 – $3.22New
Aug 26, 2026Adjusted diluted EPS growthFY2027+9%Reaffirmed
Aug 26, 2026Adjusted effective income tax rateFY202720%New
Aug 26, 2026Net income growthFY2027+27%New
Aug 26, 2026Diluted EPS growthFY2027+27%Reaffirmed
Aug 26, 2026Adjusted EBITDA growthFY2027+3%New
Aug 26, 2026Adjusted net income growthFY2027+9%Raised
Aug 26, 2026Net incomeFY2027$122.00M – $132.00MNew
Aug 26, 2026Adjusted net incomeFY2027$140.00M – $147.00MNew
Aug 26, 2026Net salesFY2027$1.55B – $1.60BNew
Aug 26, 2026Net sales growthFY2027+4%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Phibro Animal Health filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. News
  3. Results
  4. News
  5. Results
  6. News
  7. Update
  8. Results
  9. News
  10. Update
  11. Results
  12. News
  13. Results
  14. News
  15. Results

See a number that looks wrong?